CNR2 and malignant colon neoplasm: As already described, CB2 has been investigated in multiple cancer types and models of inflammation, and there are controversial results regarding the effect on tumor progression: CB2 expression is associated with a poor prognosis in humans, CB2 antagonists suppress tumorigenesis, CB2 activation promotes tumorigenesis in models of colon cancer, CB2 agonists inhibit carcinogenesis, etc. [16,17,18,21,63,64,65].